ForbesWed, 20 May 2026 16:10:19 GMTInside Incyte's $120 Million AI For Drug Development DealINCY+1.55%
Seeking AlphaTue, 19 May 2026 17:40:43 GMTIncyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptINCY+1.55%
MarketBeatMon, 18 May 2026 05:10:54 GMTIncyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts BuildINCY+1.55%
Seeking AlphaWed, 13 May 2026 23:20:50 GMTIncyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks TranscriptINCY+1.55%
Zacks Investment ResearchWed, 06 May 2026 14:41:23 GMTWhy Incyte (INCY) is a Top Value Stock for the Long-TermINCY+1.55%
Zacks Investment ResearchTue, 05 May 2026 14:45:43 GMTHere's Why Incyte (INCY) is a Strong Growth StockINCY+1.55%
Zacks Investment ResearchMon, 04 May 2026 14:51:26 GMTWhy Incyte (INCY) is a Top Momentum Stock for the Long-TermINCY+1.55%
Seeking AlphaTue, 28 Apr 2026 18:21:50 GMTIncyte Corporation (INCY) Q1 2026 Earnings Call TranscriptINCY+1.55%
Zacks Investment ResearchTue, 28 Apr 2026 17:03:24 GMTINCY Q1 Earnings and Revenues Beat Estimates on Higher Product SalesINCY+1.55%
Zacks Investment ResearchTue, 28 Apr 2026 14:31:14 GMTCompared to Estimates, Incyte (INCY) Q1 Earnings: A Look at Key MetricsINCY+1.55%
Zacks Investment ResearchTue, 28 Apr 2026 13:16:24 GMTIncyte (INCY) Beats Q1 Earnings and Revenue EstimatesINCY+1.55%
Investors Business DailyTue, 28 Apr 2026 13:04:38 GMTIncyte Stock Reverses, Though Questions Face Its Key Growth ProductINCY+1.55%
Zacks Investment ResearchFri, 24 Apr 2026 13:51:07 GMTIncyte Gears Up to Report Q1 Earnings: What Can Investors Expect?INCY+1.55%
Seeking AlphaThu, 23 Apr 2026 17:30:00 GMTIncyte Q1 Preview: The Growth Story Remains IntactINCY+1.55%
Zacks Investment ResearchTue, 21 Apr 2026 15:06:36 GMTIncyte (INCY) Reports Next Week: Wall Street Expects Earnings GrowthINCY+1.55%
Zacks Investment ResearchMon, 20 Apr 2026 14:42:32 GMTHere's Why Incyte (INCY) is a Strong Value StockINCY+1.55%
Zacks Investment ResearchMon, 30 Mar 2026 20:00:30 GMTIncyte Reports Strong 54-Week Data From Late-Stage Skin Disorder StudyINCY+1.55%
Seeking AlphaTue, 17 Mar 2026 14:24:36 GMTIncyte: Valued Like A Single-Drug Company Despite Diversifying RevenueINCY+1.55%
Seeking AlphaWed, 11 Mar 2026 15:02:17 GMTIncyte Corporation (INCY) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptINCY+1.55%
